Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks with Bloomberg's Dani Burger.

US Commerce Secretary Howard Lutnick Talks AI, US-Canada Trade
13:45

Chevron CEO Mike Wirth Talks Venezuela JV, Hormuz Flows
10:44

US Energy Secretary Chris Wright Talks Venezuela Oil Production
10:14